Savara Pharmaceuticals Secures $16,000,000 Series B Funding Round

  • Feed Type
  • Date
    3/20/2013
  • Company Name
    Savara Pharmaceuticals
  • Mailing Address
    5900 Shepherd Mountain Cove Austin, TX 78730
  • Company Description
    Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
  • Website
    http://www.savarapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $16,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Savara Pharmaceuticals will use the Series B funds to support a phase IIa clinical program evaluating the efficacy of AeroVancTM (vancomycin hydrochloride inhalation powder) for the treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients.
  • M&A Terms
  • Venture Investor
    Pasadena Angels
  • Venture Investor
    Tech Coast Angels
  • Venture Investor
    Central Texas Angel Network
  • Venture Investor
    Keiretsu Forum – Southern California
  • Venture Investor
    North Texas Angel Network

By posting a comment, you agree to our terms and conditions.